basimglurant

Basimglurant is an investigational small molecule drug developed as a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). It is being studied for its potential to treat neurological and psychiatric conditions such as trigeminal neuralgia, major depressive disorder (MDD), fragile X syndrome (FXS), and tuberous sclerosis complex. Basimglurant has shown high specificity for mGluR5 and a favorable safety profile in preclinical and clinical studies. The drug is orally administered with good bioavailability and a long half-life supporting once-daily dosing[3][7][1].

Other names

2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-yl)ethynylpyridine2-chloro-4-[2-[1-(4-fluorophenyl)-2,5-dimethylimidazol-4-yl]ethynyl]pyridine